Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

Wet Age-related Macular Degeneration Clinical Trial

— GALATIR  

Official title:

Multicentre Double Blind Randomized Clinical Study Evaluating The Efficacy and Safety of BCD-021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in Patients With Neovascular Wet Age-related Macular Degeneration

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02036723
• Other study ID #: GALATIR/BCD-021-3
• Secondary ID: GALATIR
• Status: Withdrawn
• Phase: Phase 3
• First received: January 13, 2014
• Last updated: March 30, 2016

Study information

• Verified date: March 2016
• Source: Biocad
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: National Health Surveillance AgencyRussia: Ministry of Health of the Russian Federation
• Study type: Interventional

Clinical Trial Summary

GALATIR is a double blind randomized clinical trial comparing efficacy and safety of BCD-021 (bevacizumab) and Lucentis® (ranibizumab) in patients with neovascular wet age-related macular degeneration. The purpose of the study is to demonstrate the non-inferiority of efficacy and safety of BCD-021 compared to Lucentis®.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

• Having signed a written informed consent form;

• Men and women;

• Patients must be from 50;

• Wet AMD in the study eye, defined as: Not previously treated active choroidal neovascular membrane (CNV), including retinal angiomatous proliferation (RAP), with oedema involving the fovea as demonstrated with optical coherence tomography (OCT) and fluorescein angiography (FA). FA shall not be older than 14 days at randomization;

• Best corrected VA for the studied eye ranging between 20/32 (6.3/10) and 20/320 (0.6/10) with EDTRS scale;

• Size of lesion < 12 disk area;

• In case of occult neovessels, proof required of recent development of the lesion:

loss of VA of at least 5 letters EDTRS (equivalent one line) in the last 3 months OR appearance of a subretinal hemorrhage OR increase in the size of the lesion (> 10%) using fluorescein angiography during the last month by comparison with the last 3 months OR appearance of OCT criteria of macular oedema type, serous separation of neuro-epithelium, separation of the pigmented epithelial during the last month;

• Only one eye of each study patient may be recruited into the study. If the non-study eye is being treated with anti-VEGF therapy, or develops wet AMD, then the same drug being used in the study eye shall be used in the non-study eye. Treatment must be given double-blind in the non-study eye as well;

• Patient's ability (in Investigator's opinion) to follow the protocol procedures;

• Male and female patients with normal reproductive function and their sexual partners are aware and willing to use voluntarily reliable methods of contraception during the whole period of the study including the screening period. This requirement does not apply to patients who underwent operative sterilization or those defined as post-menopausal (confirmed by medical history documentation) within last 2 years. Reliable methods of contraception suggest using 1 barrier method in combination with 1 of the following methods: spermicides, intra-uterine device etc.

Exclusion Criteria:

• Previous or current treatment with intravitreal injection of an anti-VEGF drug (ranibizumab, bevacizumab, aflibercept or pegaptanib, etc.) in the studied eye;

• Other healing treatment in the studied eye during the last 3 months before the first injection;

• Former vitrectomy in the study eye;;

• Medical history of photocoagulation in the studied eye;

• Involvement in another clinical study (studied eye and/or the other eye);

• Subretinal haemorrhage reaching the fovea centre, with a size > 50% of the lesion area;

• Fibrosis or retrofoveal retinal atrophy in the studied eye;

• Retinal pigment epithelial tear reaching the macula in the studied eye;

• Choroidal neovascularisation not related to a AMD in the studied eye;

• Medical history of intravitreal medical device in the studied eye;

• Active or suspected ocular or peri-ocular infection;

• Acute conjunctivitis, keratitis, scleritis, or endophthalmitis;

• Serious active intra-ocular inflammation in the studied eye;

• Macula-foramen of the studied eye;

• Myopia larger than -8 diopter;

• Former corneal grafting of the studied eye;

• Medical history of auto-immune or idiopathic uveitis;

• Proved diabetic retinopathy;

• Intra-ocular pressure = 25 mmHg despite two topical hypotonic treatments;

• Medical history of intra-ocular surgery within 2 months before the first injection in the studied eye;

• Aphakia or lack of lens capsule (not removed by laser) in the studied eye;

• Any illness or ocular condition that would require an intra-ocular surgery in the studied eye within 12 months after the inclusion;

• Known hypersensitivity to ranibizumab, bevacizumab, or another drug composite of the medicinal products used; allergy to fluorescein, indocyanine green, anaesthetic eye drops;

• Arterial hypertension that is not controlled by an appropriate treatment;

• Previous or current treatment with systemic administration of bevacizumab;

• Pregnancy and breast-feeding;

• Any determined immunodeficiency;

• Syphilis, HIV, hepatitis B, any history of hepatitis C virus;

• Any mental disorder, including major depression and/or suicidal thoughts in anamnesis that can, in Investigator's opinion, create a risk for the patient or influence the patient's ability to follow the study protocol;

• Drug addiction, alcoholism.

• Presence or history of malignant neoplasm (including lymphoproliferative disease), with the exception of: Adequately treated basal cell carcinoma and cervical carcinoma in situ; Any malignancy with complete remission of more than 5 years;

• Simultaneous participation in any other clinical trial, as well as former participation in other clinical trials within 3 months before this study initiation; previous participation in this study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Macular Degeneration
• Wet Age-related Macular Degeneration

Intervention

Drug:
• Bevacizumab
Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
• Ranibizumab
Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.

Locations

Country	Name	City	State
Brazil	Universidade Federal de Minas Gerais Hospital das Clínicas	Belo Horizonte
Brazil	Hospital dos Olhos do Paraná	Curitiba	Paraná
Brazil	Universidade Estadual de Londrina	Londrina	Parana
Brazil	UERJ Hospital Universitário Pedro Ernesto	Rio de Janeiro
Brazil	Universidade Federal do Rio de Janeiro Hospital Clementino Fraga Filho	Rio de Janeiro
Brazil	Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto	São Paulo
Brazil	Universidade Federal de São Paulo Hospital São Paulo	São Paulo
Russian Federation	Republican Clinical Eye Hospital	Kazan	Republic of Tatarstan
Russian Federation	Scientific and Research Institute named after Helmholtz	Moscow
Russian Federation	Regional Clinical Ophthalmic Hospital named TI Yeroshevsky	Samara
Russian Federation	IRTC "Eye Microsurgery" named after academician SN Fedorov "	St. Petersburg
Russian Federation	Municipal Advisory and Diagnostic Centre number 1	St. Petersburg
Russian Federation	St. Petersburg State Medical University named after academician IP Pavlova	St. Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Biocad

Countries where clinical trial is conducted

Brazil,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	• Proportion of patients losing fewer than 15 letters on EDTRS chart at month 12		week 52	No
Secondary	• Frequency of ocular and systemic adverse events (AE) and serious adverse events (SAE) that are related, in Investigator's opinion, to AMD therapy		week 52	Yes
Secondary	• Frequency of AE and SAE with toxicity level of 3-4 that are related, in Investigator's opinion, to AMD therapy		week 52	Yes
Secondary	• Number of cases of early withdrawal from the study caused by AE or SAE		week 52	Yes
Secondary	• Number of patients who have binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 12		screening, week 52	No
Secondary	• The mean titer of binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 12		screening, week 52	No
Secondary	• Mean change in VA score, measured on the EDTRS scale at month 12		week 52	No
Secondary	• Average number of injections and time before re-injection		week 52	No
Secondary	• Lesion size at month 6 and month 12 (by angiography)		week 26, 52	No
Secondary	• Lesion leakage at month 6 and month 12		week 26, 52	No
Secondary	• Change in fluid and foveal thickness on OCT during the study		week 52	No
Secondary	• Retinal sensitivity measured by microperimetry at screening, at month 6 and month 12		screening, week 26, 52	No
Secondary	• Timing of visual improvement after initiation of therapy		week 52	No